nwinnovation
High Technology News and Information for the Pacific Northwest Region
Home
Mobile
News and Events
  • Headlines
  • Interviews
  • Events
  • Jobs
  • VC Funds
    		•
    Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
  • People
  • Exits
  • VentureMap
  • PowerSearch
  • FundingSearch
  • Stats
  • Dashboard
  • Satellite
  • Post Jobs
    • About
  • About
  • Contact Us
    		•
    Search News
    Subscribe with Bloglines Subscribe in NewsGator Online Add to My Yahoo
    Monday, November 16, 2009

    OVP Leads $30M Investment in Stem Cell Firm


    OVP Venture Partners has led a $30M investment in a San Diego, California firm focused on stem cell therapy, according to Fate Therapeutics. Fate said that OVP Venture Partners led the firm's latest, Series B funding round, and will be adding Carl Weissman to its board. Fate Therpauetics is developing stem cell treatments, including treatments for leukemia and lymphona. Participating in the funding with OVP was Astellas Venture Management, Genzyme Ventures, and an un-named corporate investor, along with prior investors ARCH Venture Partners, Polaris Venture Partners and Venrock.
    posted on Monday, November 16, 2009


    Related companies:
    OVP Venture Partners

    Related stories:
    > Fate Therapeutics Launches Stem Cell Firm
    > OVP Names Technical Advisor
    > Cell Therapeutics Shuts Italian Operations
    > Cell Therapeutics Cuts 62 in Italy
    > Cell Therapeutics Closes Italian Branch
    Sign up to receive updates via our daily email newsletter

    Enter your email:


    Previous Issues

     Tuesday, February 9, 2010
    Monday, February 8, 2010
    Friday, February 5, 2010
    Thursday, February 4, 2010
    Wednesday, February 3, 2010